Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination

Scott T. Rottinghaus, Gregory A. Poland, Robert M. Jacobson, Lori J. Barr, Mike J. Roy

Research output: Contribution to journalArticle

121 Scopus citations


A novel DNA vaccine against hepatitis B virus was administered intraepidermally by particle-mediated epidermal delivery (PMED) to 16 human subjects who demonstrated absent or non-sustainable responses to conventional hepatitis B vaccination. Eleven subjects received three doses of vaccine at 56-day intervals, and five subjects received only a single vaccination. Each dose of vaccine contained 4μg of plasmid DNA encoding the hepatitis B surface antigen (HBsAg). The vaccine was safe and well tolerated. Remarkably, the DNA vaccine elicited antibody responses in 12 of the 16 subjects after a licensed subunit vaccine failed to induce a lasting response after ≥3 vaccinations. This study provides evidence in humans for protective immunogenicity of a particle-mediated DNA vaccine in subjects who have responded suboptimally to conventional vaccination.

Original languageEnglish (US)
Pages (from-to)4604-4608
Number of pages5
Issue number31
StatePublished - Nov 7 2003



  • DNA vaccines
  • Hepatitis B
  • Immunogenicity
  • Particle-mediated delivery
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this